Rocket Pharmaceuticals appoints Dr. Mikael Dolsten to board

ROCKET PHARMACEUTICALS, INC.

Dr. Mikael Dolsten appointed to board effective September 9, 2024.
Dolsten is Chief Scientific Officer and President, Pfizer R&D since July 2023.
Granted options to purchase 27,545 shares (vesting over 3 years) and 22,988 shares (vesting in 1 year) at closing market price.
Entered standard indemnification agreement with the company.
No arrangements with other persons or family relationships with directors/officers.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Dr. Mikael Dolsten

Director

RCKT · ROCKET PHARMACEUTICALS, INC.

Effective: 2024-09-09
Filed: September 11, 2024, 7:59 PM ET

appointed Dr. Mikael Dolsten, M.D., Ph.D. to the Board, effective September 9, 2024.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Mikael Dolsten was appointed as Director at ROCKET PHARMACEUTICALS, INC..

Action: appointed
Role: Director

Exact text from the filing

appointed Dr. Mikael Dolsten, M.D., Ph.D. to the Board, effective September 9, 2024.

View on SEC.gov

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-24-040837

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.